adjuvant chemotherapy-Larissa University Hospital-rectal cancer

adjuvant chemotherapy-Larissa University Hospital-rectal cancer refers to the specific adjuvant chemotherapy protocol utilized in a randomized controlled trial (NCT04849377) led by Larissa University Hospital for patients with locally advanced rectal cancer. This intervention serves as the standard-of-care control arm, administered following neoadjuvant chemoradiotherapy and surgical resection. The protocol specifies the use of either the CAPOX regimen (a combination of the oral fluoropyrimidine capecitabine and the intravenous platinum agent oxaliplatin) for 8 cycles, or the FOLFOX regimen (a combination of intravenous folinate, fluorouracil, and oxaliplatin) for 12 cycles. These regimens are designed to eliminate residual micrometastatic disease and reduce the risk of recurrence. Capecitabine and fluorouracil function as antimetabolites by inhibiting thymidylate synthase, thereby disrupting DNA synthesis. Oxaliplatin acts by forming covalent DNA adducts that lead to intra- and inter-strand cross-links, inducing apoptosis. Folinate is included in the FOLFOX regimen as a biochemical modulator to stabilize the binding of fluorouracil's active metabolite to thymidylate synthase, enhancing its cytotoxic efficacy.

Other names

CAPOXFOLFOXcapecitabine + oxaliplatinfolinate + fluorouracil + oxaliplatinAdjuvant Chemotherapy (Larissa University Hospital protocol)